Karl Kieburtz And NotMaryland
List of bibliographic references
Number of relevant bibliographic references: 12.| Ident. | Authors (with country if any) | Title |
|---|---|---|
| 000107 | Karl Kieburtz [États-Unis] | Twice‐daily, low‐dose pramipexole in early Parkinson's disease: A randomized, placebo‐controlled trial |
| 000248 | C. Warren Olanow [États-Unis] ; Kathryn B. Wunderle [États-Unis] ; Karl Kieburtz [États-Unis] | Milestones in movement disorders clinical trials: Advances and landmark studies |
| 000511 | Peggy Auinger [États-Unis] ; Karl Kieburtz [États-Unis] ; Michael P. Mcdermott [États-Unis] | The relationship between uric acid levels and Huntington's disease progression |
| 000668 | Fabrizio Stocchi [Italie] ; Olivier Rascol [France] ; Karl Kieburtz [États-Unis] ; Werner Poewe [Autriche] ; Joseph Jankovic [États-Unis] ; Eduardo Tolosa [Espagne] ; Paulo Barone [Italie] ; Anthony E. Lang [Canada] ; C. Warren Olanow [Italie, États-Unis] | Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: The STRIDE‐PD study |
| 000757 | C. Warren Olanow [États-Unis, Italie] ; Karl Kieburtz [États-Unis] | Defining disease‐modifying therapies for PD—A road map for moving forward |
| 000C20 | C. Warren Olanow [États-Unis] ; Karl Kieburtz [États-Unis] ; Anthony H. V. Schapira [Royaume-Uni] | Why have we failed to achieve neuroprotection in Parkinson's disease? |
| 000E06 | Samuel A. Frank [États-Unis] ; Renee Wilson [États-Unis] ; Robert G. Holloway [États-Unis] ; Carol Zimmerman [États-Unis] ; Derick R. Peterson [États-Unis] ; Karl Kieburtz [États-Unis] ; Scott Y. H. Kim [États-Unis] | Ethics of sham surgery: Perspective of patients |
| 001311 | J. Antonelle Demarcaida [États-Unis] ; Steven R. Schwid [États-Unis] ; William B. White [États-Unis] ; Karen Blindauer [États-Unis] ; Stanley Fahn [États-Unis] ; Karl Kieburtz [États-Unis] ; Matthew Stern [États-Unis] ; Ira Shoulson [États-Unis] | Effects of tyramine administration in Parkinson's disease patients treated with selective MAO‐B inhibitor rasagiline |
| 001788 | Karl Kieburtz [États-Unis] | Designing neuroprotection trials in Parkinson's disease |
| 001829 | Andrew Siderowf [États-Unis] ; Michael Mcdermott [États-Unis] ; Karl Kieburtz [États-Unis] ; Karen Blindauer [États-Unis] ; Sandra Plumb [États-Unis] ; Ira Shoulson [États-Unis] | Test–Retest reliability of the Unified Parkinson's Disease Rating Scale in patients with early Parkinson's disease: Results from a multicenter clinical trial |
| 001885 | Ira Shoulson [États-Unis] ; David Oakes [États-Unis] ; Stanley Fahn [États-Unis] ; Anthony Lang ; J. William Langston [États-Unis] ; Peter Lewitt [États-Unis] ; C. Warren Olanow [États-Unis] ; John B. Penney ; Caroline Tanner [États-Unis] ; Karl Kieburtz [États-Unis] ; Alice Rudolph [États-Unis] | Impact of sustained deprenyl (selegiline) in levodopa‐treated Parkinson's disease: A randomized placebo‐controlled extension of the deprenyl and tocopherol antioxidative therapy of parkinsonism trial |
| 002566 | Karl Kieburtz [États-Unis] | A controlled trial of lazabemide (RO19–6327) in untreated Parkinson's disease |
| This area was generated with Dilib version V0.6.23. |  |